Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

U.S. approves Aralez pill for heart patients; stock jumps

Published 2016-09-15, 11:54 a/m
© Reuters.  U.S. approves Aralez pill for heart patients; stock jumps
ARLZQ
-

By Toni Clarke

Sept 15 (Reuters) - The U.S. Food and Drug Administration on Thursday approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.

The pill, Yosprala, was developed by Canada-based Aralez Pharmaceuticals Inc ARLZ.O ARZ.TO , whose shares rose nearly 10 percent on the news.

Yosprala is designed to protect against gastrointestinal side effects, including stomach bleeding, that can occur in some patients who take daily aspirin.

Daily aspirin therapy is a standard treatment for patients who have had a heart attack to reduce the risk of a second heart attack. About 200,000 Americans a year who have one heart attack go on to have a second.

Yosprala combines aspirin and omeprazole in a way that releases the omeprazole first to protect the stomach. The aspirin is then slowly released into what the company describes as a "gastroprotective zone," thus reducing the risk of stomach ulcers.

In an interview, Aralez's chief executive, Adrian Adams, said the out-of-pocket cost to patients would be less than $1 a day. He said the company is "very conscious" of the controversy surrounding high pricing of older drugs.

Adams said the price of Yosprala to patients will be equivalent to what they would pay to buy the products separately over the counter. He said he expects the drug to generate peak sales of about $200 million a year.

In theory, a patient could buy over-the-counter omeprazole and aspirin and take them together, but Adams said in order for the omeprazole to be protective, it would have to be taken half an hour to an hour before the aspirin, an inconvenient and haphazard regimen that is avoided with Yosprala.

The company said it is expanding its U.S. sales force to 110 from 85 this month and plans the first promotional launch of the drug in the first week in October.

The company's shares rose 55 cents, or 9.9 percent, to $6.00 in morning trading on the Nasdaq Stock Exchange.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.